Compare Gilead Sciences, Inc. (GILD) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MINISO Group Holding Ltd — how do they compare? Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B), while MINISO Group Holding Ltd trades at $12.03 (market cap $3.62B). The key difference: Gilead Sciences, Inc. is far larger — about 46.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| GILD | MNSO | |
|---|---|---|
Market Cap | $168.35B | $3.62B |
Sector | Health | Technology |
52-Week High | $155.80 | $26.63 |
52-Week Low | $110.56 | $11.30 |
Enterprise Value | $191.42B | $4.29B |
Dividend Yield | 2.42% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MNSO trades at $12.55, showing minimal daily movement (-0.08%). The stock exhibits neutral technical signals with bearish moving averages, trading near key support at $12. Fundamentally, the company reported strong Q1 2026 earnings that beat expectations with 28.5% revenue growth, though recent quarters showed mixed results. The company announced a HK$2 billion share repurchase program in June 2026, signaling management confidence in undervalued shares.
MNSO presents a compelling value opportunity with attractive valuation ratios (P/E 12.65, P/S 1.15) and improving profitability (2026 net margin projected at 8.98%). However, investors face risks from margin compression and volatile quarterly performance. With 75% analyst buy ratings and technical support at current levels, the stock offers upside potential but requires monitoring of execution consistency and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
